Oncology & Cancer

Five-year survival less than 40 percent in seniors with DLBCL

(HealthDay)—Overall survival among older adults with diffuse large B-cell lymphoma (DLBCL) has improved over time, but five-year survival is less than 40 percent, according to a study published online June 12 in Leukemia ...

Medications

Adding bevacizumab improves overall survival in NSCLC

(HealthDay)—The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue ...

Oncology & Cancer

Immunotherapy drug shows potential to cure advanced lung cancer

In a new study including Yale Cancer Center and Smilow Cancer Hospital researchers, the cancer immunotherapy drug pembrolizumab (Keytruda), increased survival for patients with advanced non-small cell lung cancer (NSCLC), ...

Medical research

Drug to treat malaria could mitigate hereditary hearing loss

The ability to hear depends on proteins to reach the outer membrane of sensory cells in the inner ear. But in certain types of hereditary hearing loss, mutations in the protein prevent it from reaching these membranes. Using ...

page 1 from 23